AR130300A1 - Derivados novedosos deuterados de pirimidin-2-il sulfonamida - Google Patents
Derivados novedosos deuterados de pirimidin-2-il sulfonamidaInfo
- Publication number
- AR130300A1 AR130300A1 ARP230102255A ARP230102255A AR130300A1 AR 130300 A1 AR130300 A1 AR 130300A1 AR P230102255 A ARP230102255 A AR P230102255A AR P230102255 A ARP230102255 A AR P230102255A AR 130300 A1 AR130300 A1 AR 130300A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- pyrimidin
- sulfonamide
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1) en donde R¹ es H, alcoxi o haloalcoxi; R² es 1,1,2,2-tetradeuterio-2-fluoro-etoxi, 1,1-dideuterio-2-fluoro-etoxi o 1,1-dideuterio-2,2-difluoro-etilo; R³ es alcoxi o haloalcoxi; X¹ es CR⁵ o N; R⁴ es H, halo, alquilo o haloalquilo; R⁵ es H o halo; y sales farmacéuticamente aceptables. Reivindicación 12: Un proceso para preparar un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 11 que comprende hacer reaccionar un compuesto de fórmula (2) con un compuesto de fórmula (3) en presencia de una base seleccionada de N,N-diisopropiletilamina, piridina, fosfato de potasio o hidruro de sodio para proporcionar un compuesto de formula (1) en donde los sustituyentes R¹, R², R³, R⁴ y X¹ son como se definió anteriormente. Reivindicación 14: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 11 para su uso en el tratamiento de una enfermedad modulada por GPR17. Reivindicación 20: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 11 para su uso en el tratamiento o profilaxis de esclerosis múltiple.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22192252 | 2022-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130300A1 true AR130300A1 (es) | 2024-11-27 |
Family
ID=83081337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102255A AR130300A1 (es) | 2022-08-26 | 2023-08-24 | Derivados novedosos deuterados de pirimidin-2-il sulfonamida |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250188061A1 (es) |
| EP (1) | EP4577538A2 (es) |
| JP (1) | JP2025527937A (es) |
| KR (1) | KR20250052376A (es) |
| CN (1) | CN119731168A (es) |
| AR (1) | AR130300A1 (es) |
| AU (1) | AU2023329097A1 (es) |
| CA (1) | CA3262954A1 (es) |
| CL (1) | CL2025000484A1 (es) |
| CO (1) | CO2025003256A2 (es) |
| CR (1) | CR20250058A (es) |
| IL (1) | IL318162A (es) |
| MX (1) | MX2025001765A (es) |
| PE (1) | PE20251077A1 (es) |
| TW (1) | TW202417424A (es) |
| WO (1) | WO2024042147A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025243046A1 (en) | 2024-05-23 | 2025-11-27 | Pheno Therapeutics Limited | Compounds |
| WO2025243044A1 (en) | 2024-05-23 | 2025-11-27 | Pheno Therapeutics Limited | Compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI857957B (zh) * | 2018-06-19 | 2024-10-11 | 德商Ｕｃｂ製藥有限公司 | 吡啶基及吡基-（氮）吲哚磺醯胺 |
| EP3584244A1 (en) * | 2018-06-20 | 2019-12-25 | UCB Pharma GmbH | Substituted alkoxypyridinyl indolsulfonamides |
| US20220388957A1 (en) * | 2019-01-17 | 2022-12-08 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
-
2023
- 2023-08-24 IL IL318162A patent/IL318162A/en unknown
- 2023-08-24 CR CR20250058A patent/CR20250058A/es unknown
- 2023-08-24 CA CA3262954A patent/CA3262954A1/en active Pending
- 2023-08-24 AR ARP230102255A patent/AR130300A1/es unknown
- 2023-08-24 CN CN202380059353.6A patent/CN119731168A/zh active Pending
- 2023-08-24 EP EP23758659.9A patent/EP4577538A2/en active Pending
- 2023-08-24 JP JP2025511827A patent/JP2025527937A/ja active Pending
- 2023-08-24 WO PCT/EP2023/073189 patent/WO2024042147A2/en not_active Ceased
- 2023-08-24 KR KR1020257005076A patent/KR20250052376A/ko active Pending
- 2023-08-24 PE PE2025000390A patent/PE20251077A1/es unknown
- 2023-08-24 AU AU2023329097A patent/AU2023329097A1/en active Pending
- 2023-08-25 TW TW112132038A patent/TW202417424A/zh unknown
-
2025
- 2025-02-12 MX MX2025001765A patent/MX2025001765A/es unknown
- 2025-02-20 CL CL2025000484A patent/CL2025000484A1/es unknown
- 2025-02-21 US US19/059,580 patent/US20250188061A1/en active Pending
- 2025-03-13 CO CONC2025/0003256A patent/CO2025003256A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024042147A2 (en) | 2024-02-29 |
| AU2023329097A1 (en) | 2024-11-21 |
| EP4577538A2 (en) | 2025-07-02 |
| CR20250058A (es) | 2025-05-09 |
| IL318162A (en) | 2025-03-01 |
| US20250188061A1 (en) | 2025-06-12 |
| JP2025527937A (ja) | 2025-08-25 |
| WO2024042147A3 (en) | 2024-05-16 |
| TW202417424A (zh) | 2024-05-01 |
| MX2025001765A (es) | 2025-05-02 |
| KR20250052376A (ko) | 2025-04-18 |
| CO2025003256A2 (es) | 2025-04-16 |
| CN119731168A (zh) | 2025-03-28 |
| PE20251077A1 (es) | 2025-04-10 |
| CL2025000484A1 (es) | 2025-06-27 |
| CA3262954A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130300A1 (es) | Derivados novedosos deuterados de pirimidin-2-il sulfonamida | |
| AR125818A1 (es) | Inhibidores de nlrp3 | |
| ES2148155T3 (es) | Procedimiento para la preparacion de compuestos de pirimidina. | |
| CU24735B1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CO6321261A2 (es) | Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados de pirazolo [1,5-a] pirimidinas procedimientos para su preparacion y usos de los mismos | |
| CU20220065A7 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| AR245447A1 (es) | Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas. | |
| PT1064281E (pt) | Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais | |
| RU2005105564A (ru) | Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса | |
| ES480053A1 (es) | Un procedimiento para la preparacion de nuevos derivados de quinazolina. | |
| AR048875A1 (es) | Un proceso para preparar montelukast y compuestos intermedios para el mismo | |
| AR123762A1 (es) | Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona | |
| PE20010300A1 (es) | Preparacion de piperidin-4-onas sustituidas | |
| CO5590934A2 (es) | Procedimiento de preparacion de derivados de equinocandina | |
| ES8307818A1 (es) | Procedimiento para preparar derivados de cefalosporina. | |
| ES8504792A1 (es) | Un procedimiento para preparar derivados de pirimidina | |
| AR051936A1 (es) | Proceso para la preparacion de pirazoles | |
| ES279017A1 (es) | Un metodo de producir una 2,4-diaminopirido (2,3-d) pirimidina | |
| AR030571A1 (es) | Proceso para preparar 2-(-piridin-4-ilamino)-pirido[2,3-d] pirimidinas e intermediarios en su sintesis | |
| ES350159A1 (es) | Procedimiento para la preparacion de derivados de benzodia-cepina. | |
| AR130133A1 (es) | Nuevos compuestos heterocíclicos | |
| PE20100146A1 (es) | Nuevos compuestos utiles en terapia para el dolor | |
| GB729967A (en) | Isonicotinic acid derivatives and process for the manufacture thereof |